

# NeoDynamics receives new order from large hospital in Germany

## **NeoDynamics has received a new order for FlexiPulse needles from Western Rhineland-Palatinate Hospital in Germany**

NeoDynamics AB (Nasdaq First North Growth Market Stockholm: NEOD.ST), a medical device company dedicated to advancing the diagnosis and care of cancer, is pleased to announce the receipt of a new order for FlexiPulse needles from Western Rhineland-Palatinate Hospital in Germany.

“We are very pleased to announce yet another order for FlexiPulse needles from Germany. Western Rhineland-Palatinate Hospital is among the top 100 rated and distinguished hospitals in Germany and it serves as academic training hospital for the University of Mains. It has a large interdisciplinary sonography department performing all kinds of biopsies. This order clearly demonstrates the commercial viability of our innovative pulse technology and its increasing acceptance by leading practitioners” says Anna Eriksrud, CEO.

### **For further information, please contact:**

Anna Eriksrud, CEO NeoDynamics AB, phone +46708 444 966 or e-mail [anna.eriksrud@neodynamics.com](mailto:anna.eriksrud@neodynamics.com)

Aaron Wong, CFO NeoDynamics AB, phone +46790 101 714 or e-mail [aaron.wong@neodynamics.com](mailto:aaron.wong@neodynamics.com)

### **About NeoDynamics**

NeoDynamics AB is a Swedish Medical Technology Company dedicated to advancing diagnosis and care of cancer. The company's first product NeoNavia®, a new innovative pulse biopsy system for ultrasound-guided tissue sampling, is currently being introduced to the market. The biopsy system is built on a patented pulse technology, based on research at the Karolinska Institutet in Sweden. NeoNavia is evaluated for breast cancer diagnosis at leading clinics in Europe and launches in USA during 2023. NeoDynamic's shares are listed on Nasdaq First North Growth Market Stockholm (ticker: NEOD). The company's Certified Adviser is Redeye AB.

### **About NeoNavia**

NeoNavia is a modern biopsy system with a completely new patented pulse technology intended for ultrasound-guided tissue sampling. Each needle type is driven by the pulse technology providing a more controlled needle insertion and precise placement of the needle in the tumor whilst enabling high-quality tissue samples from both breasts and lymph nodes. The pulse biopsy system NeoNavia is designed to offer clinicians and patients accurate lesion targeting and high tissue yield for correct diagnosis and individualized treatment.

### **About Karolinska Institute**

The Karolinska Institute is consistently ranked amongst the world's best medical schools, ranking 6th worldwide for medicine in 2021. The Nobel Assembly at the Karolinska Institute awards the Nobel Prize in Physiology or Medicine.

## Attachments

[NeoDynamics receives new order from large hospital in Germany](#)